{"id":"NCT03629184","sponsor":"Hoffmann-La Roche","briefTitle":"Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms","officialTitle":"A Multicenter, Randomized, Double-Blind, Active (Oseltamivir)-Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Otherwise Healthy Pediatric Patients 1 to <12 Years of Age With Influenza-Like Symptoms","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-20","primaryCompletion":"2019-04-03","completion":"2019-04-03","firstPosted":"2018-08-14","resultsPosted":"2020-04-29","lastUpdate":"2020-04-29"},"enrollment":173,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Influenza"],"interventions":[{"type":"DRUG","name":"Baloxavir Marboxil","otherNames":[]},{"type":"DRUG","name":"Oseltamivir","otherNames":[]}],"arms":[{"label":"Baloxavir Marboxil","type":"EXPERIMENTAL"},{"label":"Oseltamivir","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to \\<12 years of age) with influenza-like symptoms.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to Day 29","effectByArm":[{"arm":"Baloxavir Marboxil","deltaMin":46.1,"sd":null},{"arm":"Oseltamivir","deltaMin":53.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":37,"countries":["United States","Costa Rica","Israel","Mexico","Poland","Russia","Spain"]},"refs":{"pmids":["32516282"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":115},"commonTop":["Vomiting","Diarrhoea","Otitis Media"]}}